Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme. Issue 1 (25th October 2019)

• Record Type: Journal Article
• Authors: Mazurek, Michał; Halperin, Jonathan L; Huisman, Menno V; Diener, Hans-Christoph; Dubner, Sergio J; Ma, Chang Sheng; Rothman, Kenneth J; Healey, Jeff S; Teutsch, Christine; Paquette, Miney; França, Lionel Riou; Lu, Shihai; Bartels, Dorothee B; Lip, Gregory Y H
• Is Part Of: Europace. Volume 22:Issue 1(2020)
• Page Start: 47
• Page End: 57
• Publication Date: 2019-10-25
• Subjects: Atrial fibrillation -- Age -- Oral anticoagulation -- GLORIA-AF; Arrhythmia -- Treatment -- Periodicals; Cardiac pacing -- Periodicals; Catheter ablation -- Periodicals; Heart -- Physiology -- Periodicals; Electrophysiology -- Periodicals; 617.4120645
• DOI: 10.1093/europace/euz278
• Languages: English
• ISSNs: 1099-5129

Abstract

Abstract: Aims: To assess antithrombotic therapy choices in relation to patient age in a large, global registry on atrial fibrillation (AF). Methods and results: Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) is an international programme involving patients with newly diagnosed AF and ≥1 risk factors for stroke. We used Phase II data (from November 2011 through December 2014), which commenced immediately following first non-vitamin K antagonist oral anticoagulants (NOACs) approval in participating countries. Of 15 092 patients (mean age 70.5 ± 11.0 years), enrolled at 982 centres, 26.9% were aged <65 years, 33.9% 65–74, 30.5% 75–84, and 8.6% ≥85 years old. Oral anticoagulant (OAC) use was 73.5%, 81.4%, 83.3%, and 82.3% (overall NOACs use was 44.4%, 49.7%, 48.7%, and 45.6%) for those aged <65, 65–74, 75–84 and ≥85 years, respectively. Corresponding proportions for antiplatelet monotherapy and no treatment were: 16.2% and 10.2%; 11.2% and 7.3%; 10.0% and 6.5%; 10.5% and 7.0%, respectively. Of those aged 65–74, 75–84, and ≥85 years, respectively, 83.7, 86.8 and 85.4% received OAC unless bleeding risk was high (HAS-BLED ≥3), whereby 64.1%, 63.5%, and 64.5% were anticoagulated, and 31.1%, 30.3%, and 31.3% received antiplatelets only. Of patients ≥85 years, OAC use was 88.1% in Europe (NOAC 45.1%), 79.5% in North America (NOAC 44.8%), and 54.1% in Asia (NOAC 40.2%). Conclusion: Despite geographic differences in OAC use, neither OAC nor NOAC uptake was lower for patients ≥85 years old compared with younger patients. Although the majority of patients was prescribed OAC at all ages, nearly one-third received antiplatelet monotherapy when bleeding risk was increased. Clinical trial registration: http://www.clinicaltrials.gov . Unique identifier: NCT01468701